Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

NLCs packed with melatonin could increase effectiveness of tamoxifen drug

Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects.

14 Jun 2016

Scientists find new way to slow growth of triple negative breast cancer

CANCER RESEARCH UK scientists have found a new way to slow the growth of the most aggressive type of breast cancer, according to research published in the journal Oncogene today (Monday).

14 Jun 2016

Study opens up possibility of developing potential hormone therapies for SSc skin disease

The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time a beneficial effect of oestrogens in experimental models of skin fibrosis that are representative of the disease process in systemic sclerosis (SSc).

13 Jun 2016

Multi-center study may help reassure breast cancer patients taking tamoxifen drug

A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.

7 Jun 2016

Taking hormone therapy drugs for additional five years improves outcomes in breast cancer patients

Breast cancer patients significantly benefit by taking hormone therapy drugs called aromatase inhibitors for an additional five years, according to a major study presented at the Plenary Session of the American Society of Clinical Oncology annual meeting in Chicago and published in the New England Journal of Medicine.

7 Jun 2016

Scientists reveal how ER+ breast cancer uses cholesterol-based molecule to evade anti-hormone treatments

New research funded by Breast Cancer Now has identified how the most common breast cancers could be using a cholesterol-based molecule to evade standard anti-hormone treatments, causing patients’ disease to return.

2 Jun 2016

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research.

17 May 2016

Combination of existing chemotherapy drugs can reduce breast cancer stem cells, improve survival

Two existing chemotherapy drugs appear to be a powerful pair in targeting errant stem cells that are making breast cancer and enabling its spread and recurrence, scientists report.

3 May 2016

Predictive statistical approach opens door to development of more effective therapies for breast cancer

Designing effective new drugs, especially drugs to fight cancer, demands that you know as much as you can about the molecular workings of cancer growth. Without that, it's like planning to fight a war against an enemy you've never seen.

29 Apr 2016

Derivatives of female sex hormones can influence natural melanin production, study suggests

When skin cells responsible for pigmentation are exposed to estrogen or progesterone, the cells respond by adjusting their melanin production, resulting in either skin darkening or lightening. Although pregnant women often experience alterations in skin pigmentation, the reason for the changes has long puzzled physicians.

27 Apr 2016

Genetic markers may influence how breast cancer patients respond to treatment

Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.

20 Apr 2016

Alcohol consumption may increase risk for breast cancer

A University of Houston researcher and his team have discovered an important link between alcohol and breast cancer by identifying a cancer-causing gene triggered by alcohol

15 Mar 2016

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify.

27 Jan 2016

Anastrozole drug effective in treating early form of breast cancer

The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women.

12 Dec 2015

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

11 Dec 2015

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

9 Dec 2015

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

9 Dec 2015

Study finds no consistent evidence that antidepressants increase complications after plastic surgery

For patients undergoing plastic surgery procedures, there's no consistent evidence that taking antidepressants increases the risk of bleeding, breast cancer, or other adverse outcomes, concludes a research review in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

31 Oct 2015

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative. This new combined evidence shows the risk was reduced by up to 20% in women who breastfed.

29 Oct 2015